Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies

Daniel A. Pearson, John Lister-James, William J. McBride, David M. Wilson, Lawrence J. Martel, Edgar R Civitello, Richard T. Dean

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Platelet-specific compounds which are radiolabeled with γ-emitting radionuclides may be particularly useful for the noninvasive in vivo detection of thrombi. The synthesis of peptides which are potent inhibitors of platelet aggregation and which contain a chelator for the radionuclide technetium-99m are described. The target compounds were designed such that stable, oxotechnetium(V) species could be prepared where the site of metal coordination was well defined. A strategy was employed where the pharmacophore -Arg-Gly-Asp-(RGD), or RGD mimetic, was constrained in a ring which was formed by the S-alkylation of a cysteine residue with an N-terminal chloroacetyl group. Binding affinities were enhanced by the replacement of arginine with the arginine mimetics S-(3-aminopropyl)cysteine and 4- amidinophenylalanine. Further enhancements could be obtained by the synthesis of oligomers which contained two or more rings containing receptor binding regions. The increase in binding affinity seen was more than that expected from a simple stoichiometric increase of pharmacophore. The most potent compounds described had IC50s of approximately 0.03 μM for the inhibition of human platelet aggregation. Two of the more potent peptides (P280 and P748) were labeled with technetium-99m and assessed in a canine thrombosis model. The 99mTc complexes of the peptides prepared in this work hold promise as thrombus imaging agents due to their high receptor binding affinity, ease of preparation, and expected rapid pharmacokinetics.

Original languageEnglish (US)
Pages (from-to)1372-1382
Number of pages11
JournalJournal of Medicinal Chemistry
Volume39
Issue number7
DOIs
StatePublished - Mar 29 1996
Externally publishedYes

Fingerprint

Platelet Glycoprotein GPIIb-IIIa Complex
Technetium
Thrombosis
Platelets
Imaging techniques
Radioisotopes
Peptides
Arginine
Pharmacokinetics
Platelet Aggregation Inhibitors
Alkylation
Chelating Agents
Platelet Aggregation
Oligomers
Cysteine
Canidae
Blood Platelets
Agglomeration
Metals

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies. / Pearson, Daniel A.; Lister-James, John; McBride, William J.; Wilson, David M.; Martel, Lawrence J.; Civitello, Edgar R; Dean, Richard T.

In: Journal of Medicinal Chemistry, Vol. 39, No. 7, 29.03.1996, p. 1372-1382.

Research output: Contribution to journalArticle

Pearson, Daniel A. ; Lister-James, John ; McBride, William J. ; Wilson, David M. ; Martel, Lawrence J. ; Civitello, Edgar R ; Dean, Richard T. / Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies. In: Journal of Medicinal Chemistry. 1996 ; Vol. 39, No. 7. pp. 1372-1382.
@article{4845e02d2a0b454487463bff0687f6cb,
title = "Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies",
abstract = "Platelet-specific compounds which are radiolabeled with γ-emitting radionuclides may be particularly useful for the noninvasive in vivo detection of thrombi. The synthesis of peptides which are potent inhibitors of platelet aggregation and which contain a chelator for the radionuclide technetium-99m are described. The target compounds were designed such that stable, oxotechnetium(V) species could be prepared where the site of metal coordination was well defined. A strategy was employed where the pharmacophore -Arg-Gly-Asp-(RGD), or RGD mimetic, was constrained in a ring which was formed by the S-alkylation of a cysteine residue with an N-terminal chloroacetyl group. Binding affinities were enhanced by the replacement of arginine with the arginine mimetics S-(3-aminopropyl)cysteine and 4- amidinophenylalanine. Further enhancements could be obtained by the synthesis of oligomers which contained two or more rings containing receptor binding regions. The increase in binding affinity seen was more than that expected from a simple stoichiometric increase of pharmacophore. The most potent compounds described had IC50s of approximately 0.03 μM for the inhibition of human platelet aggregation. Two of the more potent peptides (P280 and P748) were labeled with technetium-99m and assessed in a canine thrombosis model. The 99mTc complexes of the peptides prepared in this work hold promise as thrombus imaging agents due to their high receptor binding affinity, ease of preparation, and expected rapid pharmacokinetics.",
author = "Pearson, {Daniel A.} and John Lister-James and McBride, {William J.} and Wilson, {David M.} and Martel, {Lawrence J.} and Civitello, {Edgar R} and Dean, {Richard T.}",
year = "1996",
month = "3",
day = "29",
doi = "10.1021/jm950112e",
language = "English (US)",
volume = "39",
pages = "1372--1382",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies

AU - Pearson, Daniel A.

AU - Lister-James, John

AU - McBride, William J.

AU - Wilson, David M.

AU - Martel, Lawrence J.

AU - Civitello, Edgar R

AU - Dean, Richard T.

PY - 1996/3/29

Y1 - 1996/3/29

N2 - Platelet-specific compounds which are radiolabeled with γ-emitting radionuclides may be particularly useful for the noninvasive in vivo detection of thrombi. The synthesis of peptides which are potent inhibitors of platelet aggregation and which contain a chelator for the radionuclide technetium-99m are described. The target compounds were designed such that stable, oxotechnetium(V) species could be prepared where the site of metal coordination was well defined. A strategy was employed where the pharmacophore -Arg-Gly-Asp-(RGD), or RGD mimetic, was constrained in a ring which was formed by the S-alkylation of a cysteine residue with an N-terminal chloroacetyl group. Binding affinities were enhanced by the replacement of arginine with the arginine mimetics S-(3-aminopropyl)cysteine and 4- amidinophenylalanine. Further enhancements could be obtained by the synthesis of oligomers which contained two or more rings containing receptor binding regions. The increase in binding affinity seen was more than that expected from a simple stoichiometric increase of pharmacophore. The most potent compounds described had IC50s of approximately 0.03 μM for the inhibition of human platelet aggregation. Two of the more potent peptides (P280 and P748) were labeled with technetium-99m and assessed in a canine thrombosis model. The 99mTc complexes of the peptides prepared in this work hold promise as thrombus imaging agents due to their high receptor binding affinity, ease of preparation, and expected rapid pharmacokinetics.

AB - Platelet-specific compounds which are radiolabeled with γ-emitting radionuclides may be particularly useful for the noninvasive in vivo detection of thrombi. The synthesis of peptides which are potent inhibitors of platelet aggregation and which contain a chelator for the radionuclide technetium-99m are described. The target compounds were designed such that stable, oxotechnetium(V) species could be prepared where the site of metal coordination was well defined. A strategy was employed where the pharmacophore -Arg-Gly-Asp-(RGD), or RGD mimetic, was constrained in a ring which was formed by the S-alkylation of a cysteine residue with an N-terminal chloroacetyl group. Binding affinities were enhanced by the replacement of arginine with the arginine mimetics S-(3-aminopropyl)cysteine and 4- amidinophenylalanine. Further enhancements could be obtained by the synthesis of oligomers which contained two or more rings containing receptor binding regions. The increase in binding affinity seen was more than that expected from a simple stoichiometric increase of pharmacophore. The most potent compounds described had IC50s of approximately 0.03 μM for the inhibition of human platelet aggregation. Two of the more potent peptides (P280 and P748) were labeled with technetium-99m and assessed in a canine thrombosis model. The 99mTc complexes of the peptides prepared in this work hold promise as thrombus imaging agents due to their high receptor binding affinity, ease of preparation, and expected rapid pharmacokinetics.

UR - http://www.scopus.com/inward/record.url?scp=0029925434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029925434&partnerID=8YFLogxK

U2 - 10.1021/jm950112e

DO - 10.1021/jm950112e

M3 - Article

VL - 39

SP - 1372

EP - 1382

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 7

ER -